TARS · Tarsus Pharmaceuticals, Inc.
$57.58
-0.62% last session
End-of-day data · updated 2026-07-24
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
35.3
Dividend yield
—
Beta
0.50
Avg volume
1M
Employees
0K
2D change
1.74%
5D change
-2.12%
10D change
4.40%
30D change
-12.71%
60D change
-5.91%
MTD change
-3.79%
YTD change
-28.46%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TARS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-21
Latest call per bank · past 12 months
Barclays
Overweight$100
+73.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | Guggenheim | Maintains | Buy | $90.00 → $89.00 |
| 2026-07-09 | HC Wainwright & Co. | Reiterates | Buy | $88.00 |
| 2026-05-04 | HC Wainwright & Co. | Reiterates | Buy | $88.00 |
| 2026-02-25 | Oppenheimer | Maintains | Outperform | $95.00 → $105 |
| 2026-02-25 | Guggenheim | Maintains | Buy | $87.00 → $90.00 |
| 2025-12-09 | Barclays | Initiates | Overweight | $0.00 → $100 |
| 2025-11-20 | Mizuho | Initiates | Outperform | $0.00 → $100 |
| 2025-11-05 | Guggenheim | Maintains | Buy | $84.00 → $87.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-24
- RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.4% below the 50-day MA ($61.56).
- Price vs 200-day MA: Trading 15.5% below the 200-day MA ($68.93).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.36) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($38.82) and high ($82.51).
TARS Price Chart
Loading chart for TARS…
Fundamentals
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$120B 4.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$68B -15.3% YTD
ARGX
argenx SE
$58B 10.0% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -32.4% YTD
ONC
BeOne Medicines Ltd.
$34B 7.6% YTD
RPRX
Royalty Pharma plc
$34B 54.2% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.